This paper examines the leadership and organizational change challenges facing Gene One, a privately held biotechnology company preparing for an initial public offering (IPO) following the death of its founder, Don Ruiz. Drawing on academic and industry sources, the paper proposes a three-part change strategy: building a heterogeneous top management team to attract investors, enhancing organizational and community reputation through media and social engagement, and improving financial discipline and documentation to meet public-market standards. The paper argues that these goals are mutually reinforcing — a stronger company is also a more IPO-ready one.
The paper applies a real academic source (Zimmerman, 2008) on top management team heterogeneity to a case-study scenario, bridging theoretical frameworks and practical business recommendations. This move — identifying a relevant concept from the literature and operationalizing it within a specific organizational context — is a hallmark of applied business and management writing at the undergraduate level.
The paper opens with a situational overview of Gene One's leadership crisis and dual organizational goals. It then presents three numbered change recommendations, each developed in its own section with rationale, supporting evidence, and implementation detail. The structure is deductive: the problem is framed first, then solutions are unpacked in order of strategic priority — people, perception, and finances.
Gene One is a highly successful private organization that has invested in and succeeded at its biotechnological endeavors. The company has been able to reduce disease in plants and trees, with the ultimate result of improving the quality of fruits and vegetables. Customer satisfaction has increased as consumers now find it more accessible to obtain healthy nutrients without added chemicals in their composition.
The mastermind behind Gene One, Don Ruiz, has recently passed away. The managerial team now faces the extremely difficult task of preparing the organization to go public through an initial public offering (IPO). Each department head is asserting the superiority of his or her division over the others. The company must maintain its upward trajectory and generate sustainable revenues while simultaneously preparing for its IPO.
Fortunately, these two goals are aligned in the sense that the more successful and reliable the company is, the greater its chances of a triumphant IPO. Given this situation, it is advisable for the current leadership team to pursue a change strategy built around three priorities: creating a heterogeneous top management team, enhancing organizational reputation, and attending closely to financial performance and documentation.
The general perception is that the managerial team at Gene One — or at any organization — must be united in order to impose its vision and convince staff members to follow its agenda. This belief holds true: an organization has little chance of success if its leaders are divided and cannot find ways to cooperate. Despite this, it is also advisable for the team to be heterogeneous rather than homogeneous.
The core distinction is straightforward. A homogeneous group is one in which members share similar features, backgrounds, and interests, whereas a heterogeneous group is characterized by members who come from different backgrounds and do not always see things the same way. It is this latter formation that is recommended for Gene One's leadership team.
A heterogeneous top management team is more reliable because it can assess threats and opportunities from a wider range of angles, draws on expertise from multiple fields, and brings broad education across several subjects. These qualities not only improve the quality of managerial decision-making but also strengthen the company's IPO prospects. Research indicates that a company with a heterogeneous top management team stands a greater chance of attracting larger amounts of capital through an initial public offering than one with a homogeneous team (Zimmerman, 2008).
In practical terms, Gene One's new leadership team should audit its members' professional skills, abilities, and educational backgrounds. If the assessment reveals that most members share similar professional profiles, the team should actively recruit more diverse specialists. The final management team at Gene One should include a financial specialist, a marketing specialist, a human resources specialist, a technology specialist, and a general manager.
Once Gene One becomes a publicly traded organization, its shares will be traded on both primary and secondary markets. Individual investors and brokers will set the retail price of the stock and determine its market value. The company will have no direct ability to control its share price (Journal of Accountancy, 1995). Nevertheless, it can influence that price through the perception that investors and brokers hold of the organization. The means by which a company can enhance its public perception are numerous, though each requires sustained financial investment.
One approach is to develop and implement strong media campaigns. These campaigns could be built around the visionary ideas of the late Don Ruiz and could highlight the benefits of healthier products obtained through biotechnology. Such campaigns would serve a dual purpose: on one hand, they would familiarize the public with Gene One and improve its reputation; on the other, they would introduce the customer base to the company's products, generating increasing demand for Gene One's goods and services.
A second approach is for Gene One to become more involved in the well-being of the communities in which it operates. The biotechnology firm could gain not only acceptance but genuine goodwill by allocating funds to social endeavors — for example, sponsoring local events such as community celebrations or sporting competitions, or offering grants to talented young students who lack the financial means to continue their education. Community engagement of this kind builds durable reputational capital that supports long-term investor confidence.
Gene One's path to a successful IPO hinges on three mutually reinforcing changes: diversifying its top management team, building its public reputation, and strengthening its financial foundations. These strategies are not in competition with each other — a more capable and credible organization is simultaneously a more attractive one to prospective investors. By pursuing all three in parallel, Gene One's new leadership team can honor the legacy of Don Ruiz while positioning the company for sustainable growth as a publicly traded entity.
You’re 71% through this paper. Sign up to read the remaining 1 section.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.